Johns Hopkins University is honored to welcome Merck CEO Robert M. Davis for a virtual conversation with Carey Business School Dean Alex Triantis as part of the Johns Hopkins Health Policy Forum.
The conversation will cover a range of topics, including Merck's role in the fight against the COVID-19 pandemic, the power of public-private partnerships in driving policy change, and a reflection on Merck's legacy of leadership in advancing drug affordability policies and actions around the word.
Please register here
Rob Davis is chief executive officer of Merck, one of the world's largest pharmaceutical companies. for more than 130 years, Merck has been developing medicines and vaccines for many of the world's most challenging diseases.
Previously, Rob served as Merck's president responsible for the company's operating divisions--Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company's chief financial officer.
Prior to joining Merck, Rob was corporate vice president and president of Baxter's Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter's renal Business, chief financial officer, and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.
Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health car workers, to deliver expert care when and where it is needed most.